SHARPE
Reported results
- Third quarter 2026 GAAP diluted earnings per share of $4.56 compared to $2.59 in Q3 2025
- Third quarter 2026 non-GAAP adjusted earnings per share of $4.69 compared to $2.92 in Q3 2025
- Third quarter 2026 revenues of $112.7 billion compared to $113.2 billion in Q3 2025
- Third quarter 2026 earnings from operations of $6.6 billion compared to $4.3 billion in Q3 2025
- Medical care ratio of 88.4% in Q3 2026 compared to 89.9% in Q3 2025
- Operating cost ratio of 12.8% in Q3 2026 compared to 13.5% in Q3 2025
Guidance
- Full year 2026 GAAP diluted earnings per share of at least $19.50
- Full year 2026 non-GAAP adjusted earnings per share of at least $20.50
Notes
The company raised its full year 2026 earnings outlook incorporating results through Q3 2026. Adjusted earnings exclude intangible amortization, net portfolio divestitures and South American impacts, and restructuring and other items. Nine-month 2026 results also provided in the release.
Price and volatility reaction
The stock moved -0.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -7.1 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 378.52 | 2026-10-12 |
| Close after release | 377.76 | 2026-10-13 |
| Realised move | -0.2% | close to close |
| 30d ATM IV change | -7.1 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-13 (8-K, Item 2.02). Read the original filing on sec.gov.